“…Other intravenous agents that accumulate significantly and are not suitable for use by infusion or multiple bolus administration outside of the ICU are morphine, midazolam, and thiopentone. Perhaps the most promising drug, particularly with regard to pharmacokinetics and dynamics, is remimazolam, which is metabolized by nonspecific tissue esterases, and has a fast onset and offset of effect [1,2]. This drug is currently undergoing further phase II and III evaluation.…”